SEROPOSITIVITY RATES FOR MEASLES, MUMPS, AND RUBELLA IgG AND COSTS ASSOCIATED WITH TESTING AND REVACCINATION

Monday, 25th of August 2014 Print
[source]Clinical and Vaccine Immunology[|source]

Maintaining population immunity against measles and rubella is important to prevent outbreaks. Currently, the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) considers receipt of one documented dose of the MMR vaccine as evidence of immunity to rubella and two documented doses of the MMR vaccine as evidence of immunity for mumps and measles. In the absence of vaccination documentation, serological testing is accepted as laboratory evidence of immunity.

In this report, the authors  investigated immunization screening practices using retrospective analysis of measles, mumps, and rubella IgG testing performed at ARUP Laboratories (Salt Lake City, UT). The report documents that Seropositivity rates were highest for rubella and lowest for mumps, before concluding that when there is a suspicion of nonimmunity, serological testing may be cheaper than vaccination.  More details on algorithms, results and recommendations are accessible at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3592343/

 

ABSTRACT

Retrospective analysis of IgG test results and patterns for measles, mumps, and rubella revealed generally high seropositivity rates, with that of mumps being the lowest. A simplified cost analysis shows that when there is a suspicion of nonimmunity, serological testing may be cheaper than vaccination.

Special Postings

What's New

Monday, 9th of March 2020

Monday, 9th of March 2020

Monday, 9th of March 2020

Monday, 9th of March 2020

Monday, 9th of March 2020
;

Highly Accessed

Website Views

47456460

External Links